Literature DB >> 10209344

Motor fluctuations in Parkinson's disease: pathophysiology and treatment.

C Colosimo1, M De Michele.   

Abstract

At the initial stages of Parkinson's disease (PD), levodopa (LD) is able to reduce most motor symptoms and to significantly improve the patient's quality of life. However, in the vast majority of patients with prolonged LD usage, some decline in efficacy occurs and motor complications eventually begin to appear. These complications consist not only of daily fluctuations in the voluntary motor performance often accompanied by involuntary movements, but also of fluctuations in cognitive, autonomic, and sensory functions. Several recent studies on LD complications in PD have led to a better understanding of their pathophysiology and of the possible therapeutic interventions, and a summary of these findings is presented in this review. Different observations now suggest that postsynaptic pharmacodynamic factors play a major role in determining fluctuations in PD. Two explanations are given: chronic intermittent dopaminergic therapy may lead to postsynaptic receptor downregulation in PD; or, receptor changes in the striatum may occur independently of treatment as a result of structural adaptation of the postsynaptic dopaminergic system to the progressive decline of the nigrostriatal pathway. The hypothesis of reversible postsynaptic changes as the main mechanism underlying a fluctuating response to LD lends itself to a possible pharmacological manipulation of the dopaminergic response to reverse, or even avoid, motor fluctuations (initial monotherapy with dopamine agonists and early combination LD/dopamine agonists). The role of peripheral pharmacokinetics factors is also critical and the use of controlled release LD formulations, of monoamine oxidase (MAO)-B and of catechol-O-methyltransferase (COMT) inhibitors may all, to a different degree, improve such phenomena. In the last decade, there has been a resurgence in surgical therapies in advanced PD, due to higher levels of accuracy and safety provided by the new surgical devices, and to a more precise localization of the target areas allowed by the neurophysiological mapping techniques. The surgical procedures currently used in advanced PD are stereotactic brain lesions (internal globus pallidus and subthalamic nucleus), chronic brain stimulation (of the same nuclei) and striatal grafting of dopamine-producing cells. All these procedures have already shown their efficacy in the management of severe fluctuations in PD, but their indications, and relative advantages and disadvantages, are still the subject of considerable debate and controversy. Copyright 1999 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10209344     DOI: 10.1046/j.1468-1331.1999.610001.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

Review 1.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Proceedings of the International Symposium on "Levodopa: Back to the Future", April 3-4, 2009, Catania, Italy.

Authors: 
Journal:  J Neurol       Date:  2010-11       Impact factor: 4.849

3.  L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.

Authors:  Jennifer M King; Gladson Muthian; Veronica Mackey; Marquitta Smith; Clivel Charlton
Journal:  Life Sci       Date:  2011-08-18       Impact factor: 5.037

4.  Effects of cognitive function on gait and dual tasking abilities in patients with Parkinson's disease suffering from motor response fluctuations.

Authors:  Meir Plotnik; Yaacov Dagan; Tanya Gurevich; Nir Giladi; Jeffrey M Hausdorff
Journal:  Exp Brain Res       Date:  2010-11-10       Impact factor: 1.972

5.  Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease.

Authors:  T Hershey; K J Black; J L Carl; L McGee-Minnich; A Z Snyder; J S Perlmutter
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

6.  Deep Brain Stimulation and Treatment Outcomes of Young- and Late-Onset (≤55 Years) Parkinson's Disease: A Population-Based Study.

Authors:  Emanuele Camerucci; Cole D Stang; Pierpaolo Turcano; Philip W Tipton; James H Bower; Anhar Hassan; Bryan T Klassen; Rodolfo Savica
Journal:  Front Neurol       Date:  2021-12-10       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.